ResultsIQ

ResultsIQ › Latest results › Strides Pharma Science Limited

Strides Pharma Science Limited Q3 FY26 results deck summary

NSE: STAR · BSE: 532531

Results deck of 30 Jan 2026, summarised by AI from the filing.

Strides Q3FY26 EBITDA ₹2,359m, highest ever, with Ex-US revenue up 20% YoY; reiterates US ~$400m by FY28.

Key takeaways

  1. US guidance Management reiterates US business revenue outlook of ~$400m by FY28.
  2. Ex-US growth Ex-US markets grew 20% YoY in Q3FY26, driven by Australia, UK and EU.
  3. Margin expansion Gross margin expanded 280bps YoY to 61.2% and EBITDA margin 160bps YoY to 19.8%.
  4. Access headwinds Access Market is tactical and dependent on donor funding, currently facing headwinds.

Original filing on BSE

Strides Pharma Science Limited Q1 FY27 results

As filed: Revenue ₹1,265 cr (+13% year on year), EBITDA ₹230 cr (+6% year on year), PAT ₹165 cr (+6% year on year), EBITDA margin 18.2% (−122 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,323 cr (+11% year on year), EBITDA ₹240 cr (+10% year on year), PAT ₹129 cr (+50% year on year), EBITDA margin 18.1% (−12 bps). Score 41 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 12 bps year on year. Tax rate 13%. Profit fell 38% from last quarter. Share price after the results: −15.4% in 30 days (Nifty 500: −2.5%).
  • Q3 FY26: Revenue ₹1,195 cr (+4% year on year), EBITDA ₹236 cr (+13% year on year), PAT ₹208 cr (+131% year on year), EBITDA margin 19.8% (+164 bps). Score 40 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin rose 164 bps year on year. Other income 44% of PBT. Profit rose ₹118 cr on a year ago, more than the ₹36.0 cr it added the year before. Share price after the results: +11.0% in 28 days (Nifty 500: +3.0%).
  • Q2 FY26: Revenue ₹1,221 cr (+2% year on year), EBITDA ₹232 cr (−2% year on year), PAT ₹132 cr (+40% year on year), EBITDA margin 19.0% (−73 bps). Score 17 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend. EBITDA margin fell 73 bps year on year. Tax rate 14%. Share price after the results: +9.9% in 28 days (Nifty 500: +0.4%).
  • Q1 FY26: Revenue ₹1,120 cr (+3% year on year), EBITDA ₹217 cr (0% year on year), PAT ₹106 cr (+56% year on year), EBITDA margin 19.4% (−57 bps). Score 18 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend. EBITDA margin fell 57 bps year on year. Tax rate 14%. Revenue fell 6% from last quarter. Revenue rose ₹32.0 cr on a year ago, against ₹158 cr the year before. Share price after the results: −5.8% in 30 days (Nifty 500: −1.9%).
  • Q4 FY25: Revenue ₹1,190 cr (+10% year on year), EBITDA ₹217 cr (−6% year on year), PAT ₹86.0 cr (+51% year on year), EBITDA margin 18.2% (−298 bps). Score 19 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were well below the company's own trend. EBITDA margin fell 298 bps year on year. Consolidated profit +760% but standalone -70%. Profit before exceptional items rose ₹44.0 cr on a year ago, against ₹45.0 cr the year before. Share price after the results: +32.6% in 29 days (Nifty 500: +0.5%).
  • Q3 FY25: Revenue ₹1,154 cr (+11% year on year), EBITDA ₹209 cr (+8% year on year), PAT ₹90.0 cr (+67% year on year), EBITDA margin 18.1% (−48 bps). Score 22 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend. EBITDA margin fell 48 bps year on year. Revenue fell 4% from last quarter. Revenue rose ₹116 cr on a year ago, against ₹173 cr the year before.
  • Q2 FY25: Revenue ₹1,201 cr (+20% year on year), EBITDA ₹237 cr (+55% year on year), PAT ₹94.0 cr, EBITDA margin 19.7% (+442 bps). Score 84 of 100, Above trend. EBITDA margin rose 442 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Strides Pharma Science Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.